Clinical Trial Update: A Research Study to Look at How a New Medicine Called NNC6019-0001 Works and How Safe it is for People Who Have Heart Disease Due to Transthyretin (TTR) Amyloidosis [Phase 2]

View source ↗

Summary

This update reports on a Phase 2 study evaluating Novo Nordisk's investigational medicine NNC6019-0001 for safety and effectiveness in transthyretin amyloid car…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Transthyretin Amyloid Cardiomyopathy

Drugs mentioned

• NNC6019-0001

Snippet

Sponsor: Novo Nordisk A/S | Conditions: Transthyretin Amyloid Cardiomyopathy (ATTR CM) | Phase 2 | Status: COMPLETED